Clinical-stage immuno-oncology company VCN Biosciences is developing a portfolio of its own uniquely designed therapeutic oncolytic adenoviruses. The company’s experienced team is currently ...

Enrollment completed in VIRAGE Phase 2b clinical trial of VCN-01 in metastatic pancreatic ductal adenocarcinoma (PDAC); topline data expected in Q2 2025 – – VCN-01 development bolstered by FDA ...

To achieve the feat, the doctors operating on the auspices of the Veterinary Council of Nigeria, (VCN), said that series of retreats have been put in place to enhance efficiency in the battle ...